MX2009000918A - Derivados de citocina. - Google Patents

Derivados de citocina.

Info

Publication number
MX2009000918A
MX2009000918A MX2009000918A MX2009000918A MX2009000918A MX 2009000918 A MX2009000918 A MX 2009000918A MX 2009000918 A MX2009000918 A MX 2009000918A MX 2009000918 A MX2009000918 A MX 2009000918A MX 2009000918 A MX2009000918 A MX 2009000918A
Authority
MX
Mexico
Prior art keywords
terminal portion
cytokine derivatives
cytokine
derivatives
polypeptides
Prior art date
Application number
MX2009000918A
Other languages
English (en)
Spanish (es)
Inventor
Oliver Hartley
Original Assignee
Mintaka Foundation For Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mintaka Foundation For Medical filed Critical Mintaka Foundation For Medical
Publication of MX2009000918A publication Critical patent/MX2009000918A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
MX2009000918A 2006-07-25 2007-07-25 Derivados de citocina. MX2009000918A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (1)

Publication Number Publication Date
MX2009000918A true MX2009000918A (es) 2009-08-26

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000918A MX2009000918A (es) 2006-07-25 2007-07-25 Derivados de citocina.

Country Status (25)

Country Link
US (2) US8686111B2 (https=)
EP (1) EP2076532B1 (https=)
JP (1) JP5224603B2 (https=)
KR (1) KR101530353B1 (https=)
CN (1) CN101511867B (https=)
AT (1) ATE490270T1 (https=)
AU (1) AU2007278894B2 (https=)
BR (1) BRPI0715331B8 (https=)
CA (1) CA2658806C (https=)
CY (1) CY1111630T1 (https=)
DE (1) DE602007010969D1 (https=)
DK (1) DK2076532T3 (https=)
ES (1) ES2361455T3 (https=)
GB (1) GB0614755D0 (https=)
HR (1) HRP20110146T1 (https=)
ME (1) ME01320B (https=)
MX (1) MX2009000918A (https=)
NZ (1) NZ575092A (https=)
PL (1) PL2076532T3 (https=)
PT (1) PT2076532E (https=)
RS (1) RS51854B (https=)
RU (1) RU2461567C2 (https=)
SI (1) SI2076532T1 (https=)
WO (1) WO2008012689A2 (https=)
ZA (1) ZA200901342B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
KR20210016398A (ko) * 2018-05-28 2021-02-15 오리온 바이오테크놀로지 스윗졀랜드 에스아에흐엘 암 치료에 사용하기 위한 ccr5 억제제
CN112469430B (zh) * 2018-05-28 2024-12-24 日内瓦大学 抑制大脑炎症的方法
EP4646232A1 (en) 2023-01-06 2025-11-12 Université de Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164818C (en) * 1993-06-09 2003-09-23 Charles D.Y. Sia Tandem synthetic hiv-1 peptides
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Also Published As

Publication number Publication date
HK1131162A1 (en) 2010-01-15
HRP20110146T1 (hr) 2011-06-30
ME01320B (me) 2013-12-20
BRPI0715331B8 (pt) 2021-05-25
DK2076532T3 (da) 2011-03-07
US20090317363A1 (en) 2009-12-24
US20130330305A1 (en) 2013-12-12
JP2009544304A (ja) 2009-12-17
RU2461567C2 (ru) 2012-09-20
EP2076532A2 (en) 2009-07-08
DE602007010969D1 (de) 2011-01-13
WO2008012689A2 (en) 2008-01-31
BRPI0715331B1 (pt) 2021-04-13
CA2658806A1 (en) 2008-01-31
AU2007278894B2 (en) 2012-08-09
CA2658806C (en) 2017-01-03
SI2076532T1 (sl) 2011-06-30
KR101530353B1 (ko) 2015-06-26
PT2076532E (pt) 2011-03-02
WO2008012689A3 (en) 2008-05-08
US8686111B2 (en) 2014-04-01
KR20090060281A (ko) 2009-06-11
RU2009106436A (ru) 2010-08-27
ES2361455T3 (es) 2011-06-17
AU2007278894A1 (en) 2008-01-31
JP5224603B2 (ja) 2013-07-03
CN101511867B (zh) 2014-04-09
BRPI0715331A2 (pt) 2013-07-16
CY1111630T1 (el) 2015-10-07
NZ575092A (en) 2011-08-26
EP2076532B1 (en) 2010-12-01
RS51854B (sr) 2012-02-29
ATE490270T1 (de) 2010-12-15
ZA200901342B (en) 2010-11-24
US9328153B2 (en) 2016-05-03
CN101511867A (zh) 2009-08-19
GB0614755D0 (en) 2006-09-06
PL2076532T3 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
NZ600731A (en) Oxyntomodulin peptide analogue
NZ600732A (en) Oxyntomodulin peptide analogue
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
NZ600690A (en) Fkbp-l and uses thereof
IN2014CN02050A (https=)
UA103215C2 (uk) Поліпептид з ксиланазною активністю
ZA200901342B (en) Cytokine derivatives
WO2008038287A3 (en) N-terminal fgf variants having increased receptor selectivity and uses thereof
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2005068494A3 (en) Chimera botulinum toxin type e
WO2007115837B1 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
NZ609216A (en) Anticancer fusion protein
EP2455461A3 (en) Lipase variants for pharmaceutical use
NZ707439A (en) Modified factor ix polypeptides and uses thereof
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2007048857A8 (es) USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2008113536A8 (en) Neurotrophic peptides
WO2007142582A8 (en) Fluorescent proteins and genes encoding them
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
WO2010057242A3 (de) Vakzin
NZ601647A (en) Variant hhip1 protein and methods and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration